Aura Biosciences, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Aura Biosciences, Inc. (AURA) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value of $30.10 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate · last filed 2024-11-12
- 2024-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $30.10M.
- 2024-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $39.40M.
- 2024-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $58.70M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value |
|---|---|
| 2024-09-30 | $30.10M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $39.40M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $58.70M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |